News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Bartomeu Massuti on Optó-TROP 01 Lung study at ASCO24
Photo taken from Bartomeu Massuti/X
Jun 1, 2024, 21:13

Bartomeu Massuti on Optó-TROP 01 Lung study at ASCO24

Bartomeu Massuti, Associate Professor at Miguel Hernandez University of Elche, shared a post on X:

“Optó-TROP 01 Lung study: Sacitumumab-Tirumoten plus Immunity-Checkpoint-Inhibitor approach in pretreated NSCLC at ASCO24: interesting results but development continues with Pembrolizumab.”

Bartomeu Massuti

Source: Bartomeu Massuti/X

ASCO24 Bartomeu Massuti cancer NSCLC OncoDaily Oncology pembrolizumab
Special Coverage
Blog
Apr 19, 2025, 17:53
Cancer Nutrition Tips: Pink Africa Foundation Highlights Healing Benefits
Blog
Apr 19, 2025, 17:21
Exploring the integration of patient-reported outcome measures in clinical practice
Blog
Apr 19, 2025, 17:17
Join our Networks and Working Groups to learn, network and grow - SIOP
Blog
Apr 19, 2025, 17:14
Re-irradiation revolution: Maximising technical advances in imaging, biology and dose evaluation at ESTRO 2025
Blog
Apr 19, 2025, 17:02
New whitepaper on navigation services and reimbursement success - Florida Cancer Specialists and Research Institute
Blog
Apr 19, 2025, 17:01
Chiara Mercinelli: Honored to have been selected for the ASCO 2025 Merit Award
Blog
Apr 19, 2025, 16:48
How EveryGrant helps organizations build impactful grant programs - Conquer Cancer, the ASCO Foundation
Blog
Apr 19, 2025, 16:44
Agenus to Reveal Phase 1 HCC Immunotherapy Data at AACR 2025
Blog
Apr 19, 2025, 16:36
Bilal Awad: Knowledge, attitudes, and self-efficacy regarding palliative care among Palestinian nurses in intensive care units
Blog
Apr 19, 2025, 16:23
Toufic Kachaamy: Thrilled to give two talks on cancer ablation at DDW2025
Blog
Apr 19, 2025, 16:23
Elvina Almuradova: Olaparib improved ORR and PFS in BRCA-mutated PSR ovarian cancer, but no OS benefit
Blog
Apr 19, 2025, 16:12
Cristian Massacesi: Visiting our AstraZeneca team in Germany to talk oncology ambitions